Comparison of two commercially available ELISAs for circulating sclerostin

Osteoporosis International

Volumn 25, Issue 5, 2014, Pages 1547-1554

  Costa, A G ^a,b   Cremers, S ^a   Dworakowski, E ^a   Lazaretti Castro, M ^b   Bilezikian, J P ^a  

^a Columbia University ^*  (United States)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

ELISA; Metabolic bone diseases; Osteoporosis; Sclerostin; Validation

Indexed keywords

EDETIC ACID; HEPARIN; SCLEROSTIN; BIOLOGICAL MARKER; BONE MORPHOGENETIC PROTEIN; GENETIC MARKER; SOST PROTEIN, HUMAN;

ADULT; ARTICLE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; ELISA KIT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FREEZE THAWING; HUMAN; HYPOPARATHYROIDISM; IDIOPATHIC OSTEOPOROSIS; LIMIT OF DETECTION; MAJOR CLINICAL STUDY; MALE; METABOLIC BONE DISEASE; OSTEOPOROSIS; PATHOPHYSIOLOGY; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; PRIMARY HYPERPARATHYROIDISM; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; BLOOD; CHRONIC KIDNEY FAILURE; COMPARATIVE STUDY; GENETIC MARKER; PROCEDURES; REPRODUCIBILITY;

BIOLOGICAL MARKERS; BONE DISEASES, METABOLIC; BONE MORPHOGENETIC PROTEINS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENETIC MARKERS; HUMANS; MALE; OSTEOPOROSIS; OSTEOPOROSIS, POSTMENOPAUSAL; RENAL INSUFFICIENCY, CHRONIC; REPRODUCIBILITY OF RESULTS;

EID: 84899651287     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-014-2635-3     Document Type: Article

References (19)

1. van Bezooijen RL, Roelen BA, Visser A, van der Wee-Pals L, de Wilt E, Karperien M, Hamersma H, Papapoulos SE, ten Dijke P, Lowik CW (2004) Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist. J Exp Med 199(6):805-814. doi: 10.1084/jem.20031454
2. Drake MT, Srinivasan B, Modder UI, Peterson JM, McCready LK, Riggs BL, Dwyer D, Stolina M, Kostenuik P, Khosla S (2010) Effects of parathyroid hormone treatment on circulating sclerostin levels in postmenopausal women. J Clin Endocrinol Metab 95(11):5056-5062. doi: 10.1210/jc.2010-0720
3. Kaji H, Imanishi Y, Sugimoto T, Seino S (2011) Comparisons of serum sclerostin levels among patients with postmenopausal osteoporosis, primary hyperparathyroidism and osteomalacia. Exp Clin Endocrinol Diabetes 119(7):440-444. doi: 10.1055/s-0031-1275661
4. Costa AG, Cremers S, Rubin MR, McMahon DJ, Sliney J Jr, Lazaretti-Castro M, Silverberg SJ, Bilezikian JP (2011) Circulating sclerostin in disorders of parathyroid gland function. J Clin Endocrinol Metab 96(12):3804-3810. doi: 10.1210/jc.2011-0566
5. Gennari L, Merlotti D, Valenti R, Ceccarelli E, Ruvio M, Pietrini MG, Capodarca C, Franci MB, Campagna MS, Calabro A, Cataldo D, Stolakis K, Dotta F, Nuti R (2012) Circulating sclerostin levels and bone turnover in type 1 and type 2 diabetes. J Clin Endocrinol Metab 97(5):1737-1744. doi: 10.1210/jc.2011-2958
6. Thambiah S, Roplekar R, Manghat P, Fogelman I, Fraser WD, Goldsmith D, Hampson G (2012) Circulating sclerostin and Dickkopf-1 (DKK1) in predialysis chronic kidney disease (CKD): relationship with bone density and arterial stiffness. Calcif Tissue Int 90(6):473-480. doi: 10.1007/s00223-012-9595-4
7. Voskaridou E, Christoulas D, Plata E, Bratengeier C, Anastasilakis AD, Komninaka V, Kaliontzi D, Gkotzamanidou M, Polyzos SA, Dimopoulou M, Terpos E (2012) High circulating sclerostin is present in patients with thalassemia-associated osteoporosis and correlates with bone mineral density. Horm Metab Res 44(12):909-913. doi: 10.1055/s-0032-1312618
8. Spatz JM, Fields EE, Yu EW, Divieti Pajevic P, Bouxsein ML, Sibonga JD, Zwart SR, Smith SM (2012) Serum sclerostin increases in healthy adult men during bed rest. J Clin Endocrinol Metab 97(9):E1736-E1740. doi: 10.1210/jc.2012-1579
9. Gaudio A, Privitera F, Battaglia K, Torrisi V, Sidoti MH, Pulvirenti I, Canzonieri E, Tringali G, Fiore CE (2012) Sclerostin levels associated with inhibition of the Wnt/beta-catenin signaling and reduced bone turnover in type 2 diabetes mellitus. J Clin Endocrinol Metab 97(10):3744-3750. doi: 10.1210/jc.2012-1901
10. Ardawi MS, Rouzi AA, Qari MH (2012) Physical activity in relation to serum sclerostin, insulin-like growth factor-1, and bone turnover markers in healthy premenopausal women: a cross-sectional and a longitudinal study. J Clin Endocrinol Metab 97(10):3691-3699. doi: 10.1210/jc.2011-3361
11. Ardawi MS, Akhbar DH, Alshaikh A, Ahmed MM, Qari MH, Rouzi AA, Ali AY, Abdulrafee AA, Saeda MY (2013) Increased serum sclerostin and decreased serum IGF-1 are associated with vertebral fractures among postmenopausal women with type-2 diabetes. Bone 56(2):355-362. doi: 10.1016/j.bone.2013.06.029
12. McNulty M, Singh RJ, Li X, Bergstralh EJ, Kumar R (2011) Determination of serum and plasma sclerostin concentrations by enzyme-linked immunoassays. J Clin Endocrinol Metab 96(7):E1159-E1162. doi: 10.1210/jc.2011-0254
13. Garnero P, Sornay-Rendu E, Munoz F, Borel O, Chapurlat RD (2013) Association of serum sclerostin with bone mineral density, bone turnover, steroid and parathyroid hormones, and fracture risk in postmenopausal women: the OFELY study. Osteoporos Int 24(2):489-494. doi: 10.1007/s00198-012-1978-x
14. van Lierop AH, van der Eerden AW, Hamdy NA, Hermus AR, den Heijer M, Papapoulos SE (2012) Circulating sclerostin levels are decreased in patients with endogenous hypercortisolism and increase after treatment. J Clin Endocrinol Metab 97(10):E1953-E1957. doi: 10.1210/jc.2012-2218
15. Durosier C, van Lierop A, Ferrari S, Chevalley T, Papapoulos S, Rizzoli R (2013) Association of circulating sclerostin with bone mineral mass, microstructure, and turnover biochemical markers in healthy elderly men and women. J Clin Endocrinol Metab 98(9):3873-3883. doi: 10.1210/jc.2013-2113
16. Weidauer SE, Schmieder P, Beerbaum M, Schmitz W, Oschkinat H, Mueller TD (2009) NMR structure of the Wnt modulator protein Sclerostin. Biochem Biophys Res Commun 380(1):160-165. doi: 10.1016/j.bbrc.2009.01.062
17. Veverka V, Henry AJ, Slocombe PM, Ventom A, Mulloy B, Muskett FW, Muzylak M, Greenslade K, Moore A, Zhang L, Gong J, Qian X, Paszty C, Taylor RJ, Robinson MK, Carr MD (2009) Characterization of the structural features and interactions of sclerostin: molecular insight into a key regulator of Wnt-mediated bone formation. J Biol Chem 284(16):10890-10900. doi: 10.1074/jbc.M807994200
18. Lierop AH, Hamdy NAT, Bezooijen RL, Löwik CW, Papapoulos SE (2011) The role of sclerostin in the pathophysiology of sclerosing bone dysplasias. Clin Rev Bone Miner Metab 10(2):108-116. doi: 10.1007/s12018-011-9123-5
19. Souberbielle JC, Friedlander G, Cormier C (2006) Practical considerations in PTH testing. Clin Chim Acta 366(1-2):81-89. doi: 10.1016/j.cca.2005.10.010